Colon Cancer Detection via ZNF304 and ZNF264 Methylation Analysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting colon cancer cells in biological samples face challenges due to insufficient specificity, as existing markers are also methylated in other types of cancer and non-cancerous tissues, making it difficult to distinguish colon cancer cells from others.
Innovation Solution
Identification and analysis of novel markers, specifically the methylation status of CpG sites in the promoter regions of ZNF304 and ZNF264 genes, to determine the presence or absence of colon cancer cells in biological samples using a kit with primer sets for methylation analysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing tumor markers (CEA, CA19-9) or known methylation markers are used for colon cancer detection, then the detection method is simple and widely available, but the specificity is insufficient because these markers are also present in other cancer types and non-cancerous tissues
Solution Approach 1:
The patent segments the detection approach by focusing on specific CpG sites within promoter regions of candidate genes rather than using broad tumor markers. This segmentation allows differentiation of colon cancer-specific methylation patterns from other cancer types, resolving the specificity issue while maintaining manageable complexity through targeted analysis of selected genomic regions
Solution Approach 2:
The invention applies local quality by examining methylation status at specific local regions (CpG sites in promoter regions) of candidate genes rather than global tumor markers. This localized approach enables detection of colon cancer-specific epigenetic changes that distinguish it from other cancers, improving specificity without requiring complex whole-genome analysis
2Measurement precision
If endoscopy is used for thorough examination of colon cancer, then detection accuracy is high, but the burden on subjects is great due to dietary restriction, laxative pre-treatment, and invasive procedure
Solution Approach 1:
The patent replaces the mechanical invasive procedure of endoscopy with a biochemical analysis method. Instead of physically inserting an endoscope to visually examine the colon, the invention uses methylation analysis of candidate genes on DNA extracted from accessible biological samples (blood, stool, or brushings), achieving comparable detection accuracy without the physical burden and discomfort of endoscopy
3Ease of operation
If occult blood tests are used for colon cancer screening, then the examination is simple and non-invasive, but sensitivity is insufficient because bleeding may not occur in all colon cancers and false positives occur with other bleeding conditions
Solution Approach 1:
The invention changes the detection parameter from detecting blood (a non-specific marker) to detecting methylation status of candidate genes (a specific molecular marker). This parameter change maintains the simplicity of using accessible biological samples while dramatically improving sensitivity and specificity by detecting epigenetic alterations that are characteristic of colon cancer regardless of whether bleeding occurs
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method allows for specific detection of colon cancer cells by distinguishing them from normal and other cancerous cells, providing accurate information on the presence or absence of colon cancer cells with high specificity and sensitivity.
Implementation Method 1
analyzing methylation status of a CpG site in a promoter region of at least one gene selected from ZNF304 (Zinc finger protein 304) and ZNF264 (Zinc finger protein 264)
Data Source
Figure 1A~1B
Figure 2A
Figure 2B
AI summary
The present invention provides a method for obtaining information on colon cancer of a subject based on the result of analysis of methylation status of a CpG site in a promoter region of at least one gene selected from ZNF304 and ZNF264 in DNA extracted from a biological sample of the subject.